NARA Discovery
Article Details
← Back to Search Results
Journal Article

State-independent inhibition of the oncogenic Kv10.1 channel by desethylamiodarone, a comparison with amiodarone

F. Gomez-Lagunas; C. Barriga-Montoya; J. P. Pardo
Pflügers Archiv - European Journal of Physiology · Vol. 476, Issue 3 · pp. 323-335 · 2024

Abstract

Kv10.1 is a voltage-dependent K channel whose ectopic expression is associated with several human cancers. Additionally, Kv10.1 has structure–function properties which are not yet well understood. We are using drugs of clinical importance in an attempt to gain insight on the relationship between pharmacology and characteristic functional properties of this channel. Herein, we report the interaction of desethylamiodarone (desAd), the active metabolic product of the antiarrhythmic amiodarone with Kv10.1: desAd binds to both closed and open channels, with most inhibition taking place from the open state, with affinity ~ 5 times smaller than that of amiodarone. Current inhibition by desAd and amiodarone is not synergistic. Upon repolarization desAd becomes trapped in Kv10.1 and thereafter dissociates slowly from closed-and-blocked channels. The addition of the Cole-Moore shift plus desAd open-pore-block time courses yields an increasing phase on the steady-state inhibition curve (H∞) at hyperpolarized holding potentials. In contrast to amiodarone, desAd does not inhibit the Kv10.1 Cole-Moore shift, suggesting that a relevant hydrophobic interaction between amiodarone and Kv10.1 participates in the inhibition of the Cole-Moore shift, which is lost with desAd.

Bibliographic Information

JournalPflügers Archiv - European Journal of Physiology
PublisherSpringer
Publication Date2024-03-01
Publication Year2024
Volume476
Issue3
Pages323-335
Document TypeJournal Article
Print ISSN0031-6768
eISSN1432-2013
DOI10.1007/s00424-023-02893-x

Access Information

NARA Access Coverage1868-01-01~Current
Journal Homepagehttps://www.springer.com/journal/424
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.